Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
05/2003
05/07/2003CN1415305A Sustained release preparation of roxithromycin
05/07/2003CN1415301A Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application
05/07/2003CN1415297A Pharmic compsn. of local administration for treating herpes zoster
05/07/2003CN1415295A Method for preparing cyproxacin polylactic acid microsphere of ciprofloxacin
05/07/2003CN1415292A Formula for improving water-solubility of armillarisin and its preparation
05/07/2003CN1415286A Antibiotic antiinflammation preparation made from extract product of Yunnan loquat as essential component
05/07/2003CN1107681C Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
05/07/2003CN1107680C Australian solanic amine salt hydrochloride its prodn. method and medical application
05/07/2003CN1107511C Medicine for treating common cold
05/07/2003CN1107509C Polygonatum sibiricum fructosans homologic mixture medicines
05/07/2003CN1107508C Method for prepn. of compsn. contg. 2,5-oligoadenylate derivatives
05/07/2003CN1107506C Medicine for treating tinea and its prepn. method
05/07/2003CN1107505C Synergistic combination of AIDS antiviral compounds and HIV inhibitor
05/07/2003CN1107503C Optically pure compoun as medicinal use
05/07/2003CN1107500C Oral rapamycin formulations
05/06/2003US6559317 Such as 2-(1-chloro-cycloprop-1-yl)-1-(2-chloro-phenyl)-3-(4,5-dihydro-1,2,4 -triazole-5-thiono-1-yl)-propan-2-ol; microbiocides; fungicides
05/06/2003US6559303 Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical
05/06/2003US6559295 Mycobacterium fol A gene that encodes for the enzyme dihydrofolate reductase
05/06/2003US6559282 Induction of antibodies against leutenizing hormone releasing hormone in mammals; obtain mammal, administer modulator, monitor immune response, evaluate for prevention of infections
05/06/2003US6559280 Controlling protein levels in eucaryotic organisms
05/06/2003US6559179 Tinvention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
05/06/2003US6559176 A method for regulating the activity of an autoinducer-2 receptor comprising contacting an autoinducer-2 receptor with an AI-2 agonist or antagonist compound.
05/06/2003US6559172 Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics
05/06/2003US6559168 Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/06/2003US6559160 These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer,
05/06/2003US6559159 Kappa opioid receptor ligands
05/06/2003US6559147 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example
05/06/2003US6559145 Heterocycle carboxamides as antiviral agents
05/06/2003US6559137 Characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient
05/06/2003US6558919 Nucleotide sequences coding polypeptide for use in the prevention and treatment of infections
05/06/2003US6558912 Screening for modulators of apoptosis; obtain cells containing apoptosis polypeptide, incubate with binding protein, expose to modulator, monitor concentration of bound protein in presence of modulator, compare to control
05/06/2003US6558692 Over-coated chewing gum formulations
05/06/2003US6558678 Good expression during growth in liquid medium in shake cultures; large scale production
05/06/2003US6558676 Immunizing mammal with noninfectious material and isolating antibodies produced
05/06/2003US6558675 Mutant human hepatitis B viral strain and uses thereof
05/06/2003US6558674 Polynucleotide vaccine formulation against pathologies of the horse
05/06/2003US6558660 Administering an amount of interleukin-9 sufficient to induce said production
05/06/2003CA2186017C Soap composition
05/06/2003CA2126691C Gapped 2' modified oligonucleotides
05/06/2003CA2115060C Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
05/06/2003CA2094144C Methods and applications for efficient genetic suppressor elements
05/06/2003CA2091263C Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
05/02/2003EP1306672A2 Method of screening drug for hepatitis C
05/02/2003EP1306377A2 Pyridyl-oxazoles and their use as cytokines inhibitors
05/02/2003EP1306375A1 Salts of benzimidazole compound and use thereof
05/02/2003EP1306371A1 Cyclic imines
05/02/2003EP1306367A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
05/02/2003EP1305447A2 Nucleic acids and pathogenic e.coli proteins, and their uses
05/02/2003EP1305438A1 Improved virus like particles based on small envelope protein from hepatitis b (hbsag-s)
05/02/2003EP1305419A2 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
05/02/2003EP1305418A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305402A1 Lipo-viro-particle complexes, preparation method and uses
05/02/2003EP1305343A2 Peptides presented by cells
05/02/2003EP1305342A2 Human kininogen d5 domain polypeptides and their use
05/02/2003EP1305332A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305316A2 Azabicyclic derivatives and their therapeutic use
05/02/2003EP1305308A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
05/02/2003EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
05/02/2003EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor
05/02/2003EP1305296A2 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305292A1 Biphenyl carboxamides
05/02/2003EP1305282A1 Pleuromutilin derivatives having antibacterial activity
05/02/2003EP1305048A2 Inhibitors of cellular efflux pumps of microbes
05/02/2003EP1305043A2 Respiratory syncytial virus vaccine
05/02/2003EP1305042A1 Compositions and methods for treatment of mucosal infections
05/02/2003EP1305038A2 Bacteriophage having multiple host range
05/02/2003EP1305036A2 Nutritional composition
05/02/2003EP1305033A1 Pharmaceutical compositions containing tobramycin and xanthan gum
05/02/2003EP1305031A2 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
05/02/2003EP1305028A2 Antimicrobial biaryl compounds
05/02/2003EP1305010A2 Dosage forms for treatment of oral mycoses
05/02/2003EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1200064B1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
05/02/2003EP1128730B1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type
05/02/2003EP1096933B1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses
05/02/2003EP1071456B1 Vaccines with an ltb adjuvant
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1036167B1 Nuclear targeting by means of streptococcal protein h
05/02/2003EP1001813B1 Pharmaceutical formulations containing voriconazole
05/02/2003EP0983037B1 Antifungal nail lacquer
05/02/2003EP0963371B1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
05/02/2003EP0948544B1 Monovalent antibody fragments
05/02/2003EP0939613B1 Mouthwash comprising calcium and phosphate ions in supersaturated solution
05/02/2003EP0934939B1 Neuraminic acid compounds
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0901482B1 Benzofuran carboxamides and their therapeutic use
05/02/2003EP0879294B1 Transduced human hematopoietic stem cells
05/02/2003EP0876146B1 Nucleoside analogs in combination therapy of herpes simplex infections
05/02/2003EP0854874B1 Macrocyclic lactone compounds and their production process
05/02/2003EP0775130B1 Method for the preparation of (+/-)-calanolide a and intermediates thereof
05/02/2003EP0772593B1 Thiopyridyl compounds for controlling helicobacter bacteria
05/02/2003EP0772592B1 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
1 ... 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 ... 1798